The expression of mRNA for a kappa opioid receptor in the substantia nigra of Parkinson's disease brain

Molecular Brain Research

Volumn 44, Issue 1, 1997, Pages 12-20

  Yamada, Mitsuhiko ^a   Groshan, Karen ^a   Phung, Chan Tran ^a   Yamada, Misa ^a   Hisamitsu, Takashi ^a,b   Richelson, Elliott ^a  

^a MAYO CLINIC   (United States)

^b SHOWA UNIVERSITY   (Japan)

Author keywords

Aging; Dopamine; Human; Melanin; Molecular cloning; Transfection

Indexed keywords

COMPLEMENTARY DNA; KAPPA OPIATE RECEPTOR; MESSENGER RNA;

ARTICLE; CONTROLLED STUDY; DNA LIBRARY; DOPAMINERGIC NERVE CELL; DOPAMINERGIC SYSTEM; HISTOCHEMISTRY; HUMAN; HUMAN TISSUE; IN SITU HYBRIDIZATION; MOLECULAR CLONING; NORTHERN BLOTTING; PARKINSON DISEASE; PERIKARYON; PRIORITY JOURNAL; SUBSTANTIA NIGRA;

AGED; AGED, 80 AND OVER; FEMALE; HUMANS; IN SITU HYBRIDIZATION; MALE; MIDDLE AGED; PARKINSON DISEASE; RECEPTORS, OPIOID, KAPPA; RNA, MESSENGER; SUBSTANTIA NIGRA;

EID: 0031027713     PISSN: 0169328X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-328X(96)00139-8     Document Type: Article

References (50)

1. Akil, H. and Watson, S.J., Cloning of kappa opioid receptors: functional significance and future directions, Prog. Brain Res., 100 (1994) 81-86.
2. Bals, K.R., Ableitner, A., Herz, A. and Shippenberg, T.S., Neuroanatomical sites mediating the motivational effects of opioids as mapped by the conditioned place preference paradigm in rats, J. Pharmacol. Exp. Ther., 264 (1993) 489-495.
3. Bals, K.R., Herz, A. and Shippenberg, T.S., Evidence that the aversive effects of opioid antagonists and kappa-agonists are centrally mediated, Psychopharmacology, 98 (1989) 203-206.
4. Baronti, F., Conant, K.E., Giuffra, M., Davis, T.L., Brughitta, G., Iadarola, M.J., Berrettini, W.H., Chase, T.N. and Mouradian, M.M., Opioid peptides in Parkinson's disease: effects of dopamine repletion, Brain Res., 560 (1991) 92-96.
5. Ben-Shachar, D. and Youdim, M.B.H., Iron, melanin and dopamine interaction: relevance to Parkinson's disease, Prog. Neuropsycopharmacol. Biol Psychiatry, 17 (1993) 139-150.
6. Chavkin, C., James, I.F. and Goldstein, A., Dynorphin is a specific endogenous ligand of the kappa opioid receptor, Science, 215 (1982) 413-415.
7. Di Chiara, G. and Imperato, A., Opposite effects of mu and kappa opiate agonists on dopamine release in the nucleus accumbens and in the dorsal caudate of freely moving rats, J. Pharmacol. Exp. Ther., 244 (1988) 1067-1080.
8. Dykstra, L.A., Gmerek, D.E., Winger, G. and Woods, J.H., Kappa opioids in rhesus monkeys. I. Diuresis, sedation, analgesia and discriminative stimulus effects, J. Pharmacol. Exp. Ther., 242 (1987) 413-420.
9. Eghbali, M., Santoro, C., Paredes, W., Gardner, E.L. and Zukin, R.S., Visualization of multiple opioid-receptor types in rat striatum after specific mesencephalic lesions, Proc. Natl. Acad. Sci. USA, 84 (1987) 6582-6586.
10. Genovese, R.F., Moreton, J.E. and Tortella, F.C., Evaluation of neuroprotection and behavioral recovery by the kappa-opioid, PD117302 following transient forebrain ischemia, Brain Res. Bull., 34 (1994) 111-116.
11. Goldstein, A. and Naidu, A., Multiple opioid receptors: ligand selectivity profiles and binding site signatures, Mol. Pharmacol., 36 (1989) 265-272.
12. Gulya, K., The opioid system in neurologic and psychiatric disorders and in their experimental models, Pharmacol. Ther., 46 (1990) 395-428.
13. Hayward, N.J., McKnight, A.T. and Woodruff, G.N., Neuroprotective effect of the kappa-agonist enadoline (CI-977) in rat models of focal cerebral ischaemia, Eur. J. Neurosci., 5 (1993) 961-967.
14. Hirsch, E., Graybiel, A.M. and Agid, Y.A., Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease, Nature, 334 (1988) 345-348.
15. Hornykiewicz, O., Dopamine (3-hydroxytyramine) and brain function, Pharmacol. Rev., 18 (1966) 925-964.
16. Iyengar, S., Kim, H.S. and Wood, P.L., Kappa opiate agonists modulate the hypothalamic-pituitary-adrenocortical axis in the rat, J. Pharmacol. Exp. Ther., 238 (1986) 429-436.
17. Javoy-Agid, F., Hirsch, E.C., Dumas, S., Duyckaerts, C., Mallet, J. and Agid, Y., Decreased tyrosine hydroxylase messenger RNA in the surviving dopamine neurons of the substantia nigra, Neuroscience, 38 (1990) 245-253.
18. Kastner, A., Hirsch, E.C., Agid, Y. and Javoy-Agid, F., Tyrosine hydroxylase protein and messenger RNA in the dopaminergic nigral neurons of patients with Parkinson's disease, Brain Res., 606 (1993) 341-345.
19. Kong, H., Raynor, K., Yano, H., Takeda, J., Bell, G.I. and Reisine, T., Agonists and antagonists bind to different domains of the cloned kappa opioid receptor, Proc. Natl. Acad. Sci. USA, 91 (1994) 8042-8046.
20. Krebs, M.O., Gauchy, C., Desban, M., Glowinski, J. and Kemel, M.L., Role of dynorphin and GABA in the inhibitory regulation of NMDA-induced dopamine release in striosome- and matrix-enriched areas of the rat striatum, J. Neurosci., 14 (1994) 2435-2443.
21. Krulich, L., Koenig, J.I., Conway, S., McCann, S.M. and Mayfield, M.A., Opioid kappa receptors and the secretion of prolactin (PRL) and growth hormone (GH) in the rat. I. Effects of opioid kappa receptor agonists bremazocine and U-50,488 on secretion of PRL and GH: comparison with morphine, Neuroendocrinology, 42 (1986) 75-81.
22. Leadem, C.A. and Yagenova, S.V., Effects of specific activation of mu-, delta- and kappa-opioid receptors on the secretion of luteinizing hormone and prolactin in the ovariectomized rat, Neuroendocrinology, 45 (1987) 109-117.
23. Leander, J.D., Zerbe, R.L. and Hart, J.C., Diuresis and suppression of vasopressin by kappa opioids: comparison with mu and delta opioids and clonidine, J. Pharmacol. Exp. Ther., 234 (1985) 463-469.
24. Li, S., Zhu, J., Chen, C., Chen, Y.W., Deriel, J.K., Ashby, B. and Liu-Chen, L.Y., Molecular cloning and expression of a rat kappa opioid receptor, Biochem. J., 295 (1993) 629-633.
25. Lowry, O.H., Rosebrough, N.J., Farr, A.L. and Randall, R.J., Protein measurement with the Folin phenol regent, J. Biol. Chem., 193 (1951) 265-275.
26. Mann, D.M.A. and Yates, P.O., Possible role of neuromelanin in the pathogenesis of Parkinson's disease, Mech. Ageing Dev., 21 (1983) 193-203.
27. Mansson, E., Bare, L. and Yang, D., Isolation of a human kappa opioid receptor cDNA from placenta, Biochem. Biophys. Res. Commun., 202 (1994) 1431-1437.
28. Mansour, A., Fox, C.A., Meng, F., Akil, H. and Watson, S.J., Kappa 1 receptor mRNA distribution in the rat CNS: comparison to kappa receptor binding and prodynorphin mRNA, Mol. Cell. Neurosci., 5 (1994) 124-144.
29. Mansour, A., Khachaturian, H., Lewis, M.E., Akil, H. and Watson, S.J., Anatomy of CNS opioid receptors, Trends Neurosci., 11 (1988) 308-314.
30. Manzanares, J., Lookingland, K.J. and Moore, K.E., Kappa opioid receptor-mediated regulation of dopaminergic neurons in the rat brain, J. Pharmacol. Exp. Ther., 256 (1991) 500-505.
31. 35S for labeling probes used in in situ hybridization, Biotechniques, 15 (1993) 506-511.
32. Millan, M.J., Kappa-opioid receptors and analgesia, Trends Pharmacol. Sci., 11 (1990) 70-76.
33. Munson, P.J. and Rodbard, D., LIGAND: a versatile computerized approach for characterization of ligand-binding systems, Anal. Biochem., 107 (1980) 220-239.
34. Noel, M.B. and Wise, R.A., Ventral tegmental injections of morphine but not U-50,488H enhance feeding in food-deprived rats, Brain Res., 632 (1993) 68-73.
35. Pfeiffer, A., Brantl, V., Herz, A. and Emrich, H.M., Psychotomimesis mediated by kappa opiate receptors, Science, 233 (1986) 774-776.
36. Roth, R.H., Wolf, M.E. and Deutsch, A.Y., Neurochemistry of mid brain dopaminergic systems. In H.Y. Meltzer (Ed.), Psychopharmacology: The Third Generation of Progress, Raven Press, New York, 1987, pp. 81-94.
37. Rothman, R.B., Bykov, V., Xue, B.G., Xu, H., De C.B., Jacobson, A.E., Rice, K.C., Kleinman, J.E. and Brady, L.S., Interaction of opioid peptides and other drugs with multiple kappa receptors in rat and human brain. Evidence for species differences, Peptides, 13 (1992) 977-987.
38. Sharif, N.A. and Hughes, J., Discrete mapping of brain Mu and delta opioid receptors using selective peptides: quantitative autoradiography, species differences and comparison with kappa receptors, Peptides, 10 (1989) 499-522.
39. Shook, J.E., Watkins, W.D. and Camporesi, E.M., Differential roles of opioid receptors in respiration, respiratory disease, and opiate-induced respiratory depression, Am. Rev. Respir. Dis., 142 (1990) 895-909.
40. Simonin, F., Gaveriaux-Ruff, C., Befort, K., Matthes, H., Lannes, B., Micheletti, G., Mattei, M.G., Charron, G., Bloch, B. and Kieffer, B., Kappa-opioid receptor in humans: cDNA and genomic cloning, chromosomal assignment, functional expression, pharmacology, and expression pattern in the central nervous system, Proc. Natl. Acad. Sci. USA, 92 (1995) 7006-7010.
41. Spanagel, R., Herz, A. and Shippenberg, T.S., Opposing tonically active endogenous opioid systems modulate the mesolimbic dopaminergic pathway, Proc. Natl. Acad. Sci. USA, 89 (1992) 2046-2050.
42. Unterwald, E., Sasson, S. and Kornetsky, C., Evaluation of the supraspinal analgesic activity and abuse liability of ethylketocyclazocine, Eur. J. Pharmacol., 133 (1987) 275-281.
43. Unterwald, E.M., Tempel, A., Koob, G.F. and Zukin, R.S., Characterization of opioid receptors in rat nucleus accumbens following mesolimbic dopaminergic lesions, Brain Res., 505 (1989) 111-118.
44. Watson, M., Isackson P.J., Makker, M., Yamada, M.S., Yamada, M., Cusack, B. and Richelson, E., Identification of a polymorphism in the human neurotensin receptor gene, Mayo Clin. Proc., 68 (1993) 1043-1048.
45. Werling, L.L., Frattali, A., Portoghese, P.S., Takemori, A.E. and Cox, B.M., Kappa receptor regulation of dopamine release from striatum and cortex of rats and guinea pigs, J. Pharmacol. Exp. Ther., 246 (1988) 282-286.
46. Wollemann, M., Benyhe, S. and Simon, J., The kappa-opioid receptor: evidence for the different subtypes, Life Sci., 52 (1993) 599-611.
47. Xie, G.X., Meng, F., Mansour, A., Thompson, R.C., Hoversten, M.T., Goldstein, A., Watson, S.J. and Akil, H., Primary structure and functional expression of a guinea pig kappa opioid (dynorphin) receptor, Proc. Natl. Acad. Sci. USA, 91 (1994) 3779-3783.
48. Yamada, M., Yamada, M. and Richelson, E., Heterogeneity of melanized neurons expressing neurotensin receptor mRNA in the substantia nigra and the nucleus paranigralis of control and Parkinson's disease brain, Neuroscience, 64 (1995) 405-417.
49. Yasuda, K., Raynor, K., Kong, H., Breder, C.D., Takeda, J., Reisine, T. and Bell, G.I., Cloning and functional comparison of kappa and delta opioid receptors from mouse brain, Proc. Natl. Acad. Sci. USA, 90 (1993) 6736-6740.
50. Zhu, J., Chen, C., Xue, J.C., Kunapuli, S., DeRiel, J.K. and Liu-Chen, L.Y., Cloning of a human kappa opioid receptor from the brain, Life Sci., 56 (1995) 201-207.